about
Molecular basis of galactosemia: mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridylyltransferaseSingle nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studiesBiochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type IIAssociation of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USACharacterization of a novel biochemical abnormality in galactosemia: deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytesA genetic factor for age-related cataract: identification and characterization of a novel galactokinase variant, "Osaka," in AsiansFinasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialModeling single nucleotide polymorphisms in the human AKR1C1 and AKR1C2 genes: implications for functional and genotyping analyses.Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.Molecular basis of disorders of human galactose metabolism: past, present, and future.Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer.Characterization of two missense mutations in human galactose-1-phosphate uridyltransferase: different molecular mechanisms for galactosemia.Molecular characterization of galactosemia (type 1) mutations in Japanese.On the molecular nature of the Duarte variant of galactose-1-phosphate uridyl transferase (GALT).Molecular characterization of the H319Q galactosemia mutation.Molecular epidemiology of hormone-metabolic loci in prostate cancer.Molecular characterization of two galactosemia mutations and one polymorphism: implications for structure-function analysis of human galactose-1-phosphate uridyltransferase.Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.Hormones and prostate cancer: current perspectives and future directions.Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade diseaseRepeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialFirst International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.Pharmacogenetics of human androgens and prostate cancer--an update.Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.A renaissance of "biochemical genetics"? SNPs, haplotypes, function, and complex diseases.Conservation of short patches of amino acid sequence amongst proteins with a common function but evolutionarily distinct origins: implications for cloning genes and for structure-function analysisAndrogen metabolic genes in prostate cancer predisposition and progression.Translesion DNA polymerases and cancerAssociations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.Genomics in breast and prostate cancer: assessment of the current state and future perspectives.Molecular epidemiology of prostate cancer: hormone-related genetic loci.Genomic biomarkers, androgen pathway and prostate cancer.Androgens and the molecular epidemiology of prostate cancer.Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.PCR-free method detects high frequency of genomic instability in prostate cancer.Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.Schwannomas exhibit distinct size-dependent gene-expression patterns.Genomics is changing personal healthcare and medicine: the dawn of iPH (individualized preventive healthcare).
P50
Q24563815-729A4551-87CE-48AA-A140-7BD051424F9BQ24654499-DBE5D080-3F61-43E1-82D7-C881708B3860Q28115080-3FDDED66-E70E-4F47-8370-D998120AE7C6Q28145189-FEAD430F-C52B-4341-BC82-02037433DA40Q28333720-897F862D-8D2A-4178-AC0D-80FE24AE42ADQ28357330-2078621D-5F7F-4BD7-A85D-B858173E35C9Q28547130-A12799EE-D4E7-4E3C-A1A3-A4A880974D73Q33789128-ED59468D-174E-44A0-8603-14CD30FF1EE2Q33831390-7527E183-C541-456B-A97F-9549BEF9961FQ34043036-B35F2E8E-7E91-4CB7-A546-DB251DA08AACQ34153498-C44EE089-E8D7-4781-956E-B7A7A7286FFCQ34248441-BEDB3E94-B538-4B9F-86EA-0A861DC9559CQ34294742-657457F0-FE8A-46A5-A132-4C1AC45BA2BAQ34336123-00E949B9-36AC-4A49-85B0-C0B534953DB9Q34365564-8E6D45AD-975C-4287-B391-1D62C02EE9B5Q34393178-03B9113A-20D8-4693-8C60-12EBC789FCE1Q34443978-9BBC2B54-47D9-4635-970C-A155BAEBAFE6Q34682926-DCF5E2CF-B79C-438F-AD34-C3A66668C0C4Q34732880-95A5B94E-7FFC-4466-B1B9-00F3AA69DC63Q35144011-D0B93063-9684-430D-AC7E-3E7B03245B0DQ35230322-4312EAC4-7073-47E8-A832-DB200E757456Q35624772-E786742D-8B66-49E7-9BF3-9AD750674A00Q35753329-7D946990-5258-431D-93FE-B87D1B70ACA2Q35894555-C0791279-4159-47AF-92E8-171A21CB6893Q35908949-7C26AB3D-EE81-495E-AF84-B2BE69911003Q36067280-90E8E2FC-3812-4498-AA82-6EEA5596C402Q36170358-3A5E6D49-F94A-43A1-BE43-25A32866ED33Q36210704-2AB1EEA1-E367-4835-B5B0-421D31650838Q36306367-3B1C10A2-8604-4EF6-BA53-96A52F1CA389Q36494150-4FBF8721-F293-43D0-AAB3-C11C55BC9F1FQ36512512-F35C03D7-110B-4CCB-9F70-16A5A48DA284Q36813755-BB4B8535-DE6F-43E6-BCAB-6D3C37EE82ECQ36845131-631AFC9F-F2B0-4A7E-9850-5237F129EA1BQ37148182-E5C520A8-249F-4D4D-B907-D06B55E224AAQ37236431-E57250BC-CE57-4212-A46E-F2EB8A3D7EABQ37294754-2E34A797-5CE5-43E4-887E-700128B939E7Q37477518-BCC1FDFE-2BDF-494A-B425-0649E2C5DA3AQ37818297-EAB31887-CC16-4354-8FA4-39970E7DB28AQ38995513-1E58BC3C-8B8C-4DD8-A50B-F941D4B2FD29Q39241201-870C79A5-A768-4FF6-8468-B12BB117E010
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Juergen Reichardt
@ast
Juergen Reichardt
@en
Juergen Reichardt
@es
Juergen Reichardt
@nl
Juergen Reichardt
@sl
type
label
Juergen Reichardt
@ast
Juergen Reichardt
@en
Juergen Reichardt
@es
Juergen Reichardt
@nl
Juergen Reichardt
@sl
prefLabel
Juergen Reichardt
@ast
Juergen Reichardt
@en
Juergen Reichardt
@es
Juergen Reichardt
@nl
Juergen Reichardt
@sl
P108
P106
P21
P31
P496
0000-0001-6458-2773